Výsledky vyhledávání - "Mouhammed A, Habra"

Akademický článek

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options

Autor: Ruaa Al-Ward, Celeste Zsembery, Mouhammed Amir Habra

Publikováno v: Endocrine Oncology, Vol 2, Iss 1, Pp R90-R101 (2023)

Adrenocortical carcinoma (ACC) is a rare cancer with high recurrence rates and heterogeneous clinical behavior. The role of adjuvant therapy remains unclear because of the challenges in collecting high-quality data for a rare cancer. The current trea

Externí odkaz: https://doaj.org/article/8e8209bb380a4e239710b4a2aca87519

Zobrazit plný text záznamu

Akademický článek

The prevalence and spectrum of reported incidental adrenal abnormalities in abdominal computed tomography of cancer patients: The experience of a comprehensive cancer center

Autor: Aiham Qdaisat, Sara Bedrose, Obadah Ezzeldin, Ahmed W. Moawad, Sai-Ching J. Yeung, Khaled M. Elsayes, Mouhammed Amir Habra

Publikováno v: Frontiers in Endocrinology, Vol 13 (2022)

BackgroundThe increasing use of computed tomography (CT) has identified many patients with incidental adrenal lesions. Further evaluation of these lesions is often dependent on the language used in the radiology report. Compared to the general popula

Externí odkaz: https://doaj.org/article/31cab415cbfb498f899633b24e390b63

Zobrazit plný text záznamu

Akademický článek

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Autor: Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, Kenneth Hess, Coya Tapia, Mingxuan Xu, Jordi Rodon Ahnert, Camilo Jimenez, Jeffrey E. Lee, Nancy D. Perrier, Russell R. Boraddus, Shubham Pant, Vivek Subbiah, David S. Hong, Abdulrazzak Zarifa, Siqing Fu, Daniel D. Karp, Funda Meric-Bernstam, Aung Naing

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)

Abstract Background Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. We investigated the efficacy and safety of pembrolizumab in patients with metastatic

Externí odkaz: https://doaj.org/article/760efaea89ee4a548eb4e75796015b79

Zobrazit plný text záznamu

Akademický článek

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature

Autor: Minas P. Economides, Amishi Y. Shah, Camilo Jimenez, Mouhammed A. Habra, Monica Desai, Matthew T. Campbell

Publikováno v: Frontiers in Endocrinology, Vol 11 (2020)

IntroductionPheochromocytomas and sympathetic paragangliomas (PPGL) are neuroendocrine catecholamine-secreting tumors that are usually localized. Metastatic disease is rare and systemic treatment consists of conventional chemotherapy and high-specifi

Externí odkaz: https://doaj.org/article/1e2e8a7189b54b33b198321c158e978c

Zobrazit plný text záznamu

Akademický článek

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

Autor: Mabel Ryder, Mouhammed Amir Habra, Matthew Campbell, Sara Bedrose, Kevin Charles Miller, Lina Altameemi, Mohamed S Ali, Sameh Nassar, Naveen Garg, Marilyne Daher, Keith D Eaton, Jeffrey Thomas Yorio, Davey B Daniel, Keith C Bible, Ashish V Chintakuntlawar

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

Background There is no effective systemic therapy for metastatic adrenal cortical carcinoma (ACC) after failure of platinum-based chemotherapy. The efficacies of single-agent oral multikinase inhibitors (MKIs) or salvage immune checkpoint inhibitors

Externí odkaz: https://doaj.org/article/4a195cbe866047b8a6068d0918bac22f

Zobrazit plný text záznamu

Akademický článek

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Autor: Priyanka C. Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L. Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D. Williams, G. Brandon Gunn, Horiana Grosu, Heath D. Skinner, Erich M. Sturgis, Neil Gross, Maria E. Cabanillas

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)

Abstract Background Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer. Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC, however, eventually these tumors acquire resistance to KI a

Externí odkaz: https://doaj.org/article/4d736957bb8a4c5dae6de6d593b78efa

Zobrazit plný text záznamu